Condensed Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenue:
Licensing fees	$ 164,975	$ 168,960	$ 336,400	$ 205,518
Peptide and consumer product sales	340,349	161,438	475,281	194,598
Consumer product sales, related party	187,779	0	239,050	0
Total revenue	693,103	330,398	1,050,731	400,116
Cost of revenue:
Cost of peptide and consumer product sales	247,698	124,745	338,995	149,234
Cost of consumer product sales, related party	104,995	0	134,525	0
Total cost of revenue	352,693	124,745	473,520	149,234
Gross profit	340,410	205,653	577,211	250,882
Operating expenses:
Research and development	90,747	208,193	315,910	375,865
Marketing and business development	244,018	160,751	448,455	286,989
General and administrative	374,889	347,115	716,681	706,860
Accounting, legal and professional fees	144,196	185,168	309,633	306,775
Depreciation and amortization	28,147	29,291	54,764	58,373
Total operating expenses	881,997	930,518	1,845,443	1,734,862
Loss from operations	(541,587)	(724,865)	(1,268,232)	(1,483,980)
Other income (expense):
Interest income	928	1,014	2,132	1,359
Interest expense on convertible notes payable	0	(35,745)	0	(64,273)
Interest expense on convertible notes payable, related party	0	(154,575)	0	(270,279)
Accretion of discount on convertible notes payable	0	(10,089)	0	(19,186)
Accretion of discount on convertible notes payable, related party	0	(18,227)	0	(33,177)
Equity in loss of affiliated company	(59,065)	0	(51,073)	0
Change in fair value of option to purchase interest in affiliated company	(25,151)	0	(17,436)	0
Total other income (expense), net	(83,288)	(217,622)	(66,377)	(385,556)
Net loss and comprehensive loss	$ (624,875)	$ (942,487)	$ (1,334,609)	$ (1,869,536)
Basic and diluted net loss per share (in Dollars per share)	$ (0.01)	$ (0.04)	$ (0.03)	$ (0.07)
Weighted average shares outstanding (in Shares)	49,720,255	25,653,512	49,720,255	25,653,512